This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes
by Sundeep Ganoria
Despite the impact of dynamic shifts in the regulatory landscape for the Zacks Medical - Generic Drugs industry, new product launches should provide some respite to RDY, SDZNY and TEVA.
Top Stock Reports for Cisco, Caterpillar & CME
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), Caterpillar Inc. (CAT) and CME Group Inc. (CME), as well as two micro-cap stocks EVI Industries, Inc. (EVI) and Franklin Financial Services Corp. (FRAF).
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
by Zacks Equity Research
Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
by Zacks Equity Research
AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Teva stock falls 14% despite better-than-expected fourth-quarter earnings results due to a weak 2025 outlook.
Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook
by Zacks Equity Research
FOLD reports preliminary fourth-quarter and full-year 2024 total revenues. The company also outlines key strategic goals for 2025.
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
by Zacks Equity Research
NMRA and HOTH are in the spotlight in the biotech sector on study data announcement.
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
by Zacks Equity Research
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
by Kinjel Shah
PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb study.
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
by Zacks Equity Research
Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.
Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?
by Zacks Equity Research
Teva Pharmaceutical Industries (TEVA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TEVA Stock Down 10% in a Month: Should You Buy the Dip?
by Kinjel Shah
Teva's reasonable valuation, an improving pipeline, and sales and profit growth potential are good enough reasons for those who own the stock to stay invested.
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance
by Zacks Equity Research
VTRS Q3 earnings and sales beat estimates. New products perform well.
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
by Zacks Equity Research
FOLD's third-quarter 2024 earnings and sales beat the Zacks Consensus Estimate. The company raises its financial guidance for 2024.
TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase
by Zacks Equity Research
TEVA reports better-than-expected third-quarter results, beating both earnings and sales estimates. However, the stock declines 7%.
Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow
by Zacks Equity Research
RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time acquisition cost and impairment charge on non-current assets.
Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
by Kinjel Shah
Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.
Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Teva Pharmaceutical Industries (TEVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales
by Zacks Equity Research
BHC's third-quarter adjusted earnings and revenues beat estimates. The increase in revenue guidance is positive.
Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Wall Street Analysts Predict a 25.1% Upside in Teva Pharmaceutical Industries (TEVA): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.1% in Teva Pharmaceutical Industries (TEVA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More
by Zacks Equity Research
FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.